Eurofins Scientific has reported sales of €1.65 billion for the first three months of 2024, up 5% on a reported basis, despite negative currency and calendar effects.

Excluding calendar effects, the bioanalytical services provider's organic revenues rose by 6.8% - a rate above its target - for its core business (i.e. excluding revenues from Covid-19 tests and reagents).

Eurofins confirms its target for adjusted EBITDA of between 1.525 and 1.575 billion euros, and sales of between 7.075 and 7.175 billion, for 2024, as well as its 2027 objectives of an adjusted EBITDA margin of 24% for sales approaching 10 billion.

Copyright (c) 2024 All rights reserved.